hVIVO (HVO) has signed a £6 million Clinical Trial Agreement with a clinical-stage biopharmaceutical company to run an influenza Human Challenge Trial (HCT) evaluating a monoclonal antibody for respiratory viral diseases.
The study will use hVIVO’s Influenza Human Challenge Study Model and is expected to begin in 2026, with revenue recognised across 2026 and 2027. The company said the deal, alongside recently announced contracts, materially improves revenue visibility for 2026.
The randomised, double-blinded placebo-controlled trial will take place at hVIVO’s quarantine facilities in Canary Wharf. Participants will be recruited through FluCamp, while all efficacy-related laboratory analysis will be carried out by hVIVO’s specialist virology laboratory.
The contract further strengthens hVIVO’s position in respiratory virus challenge studies and highlights growing demand for integrated clinical development services. The company said its end-to-end offering combines participant recruitment, clinical trial delivery and specialist virology analytics.
hVIVO’s Chief Executive Officer Yamin ‘Mo’ Khan said: “hVIVO's ability to deliver integrated recruitment, clinical trials and specialist virology analytics enables our clients to evaluate innovative assets rapidly and rigorously, delivering clear, value-generating data. This study reflects the strength of our end-to-end offering and our continued focus on supporting partners developing differentiated solutions for influenza prevention.”
Seasonal influenza is estimated to cause about 1 billion cases annually worldwide, including between 3 million and 5 million severe cases and up to 650,000 deaths each year. To date, hVIVO has inoculated more than 5,000 healthy participants across 2,477 influenza, RSV and other viral HCTs.
View from Vox
This latest contract adds further momentum to hVIVO’s growing order book and reinforces the commercial appeal of its specialist human challenge platform. Furthermore, the spread of revenue recognition across 2026 and 2027 provides improved earnings visibility while underlining continued investment in next-generation respiratory disease therapies.